Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Patrick Yung Chih Wen, M.D.

Co-Author

This page shows the publications co-authored by Patrick Wen and Raymond Huang.
Connection Strength

8.432
  1. Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro Oncol. 2020 12 18; 22(12):1822-1830.
    View in: PubMed
    Score: 0.911
  2. Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro Oncol. 2019 02 14; 21(2):234-241.
    View in: PubMed
    Score: 0.801
  3. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019 01 01; 21(1):26-36.
    View in: PubMed
    Score: 0.795
  4. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. Magn Reson Imaging Clin N Am. 2016 Nov; 24(4):705-718.
    View in: PubMed
    Score: 0.678
  5. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81.
    View in: PubMed
    Score: 0.637
  6. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol. 2015; 6:33.
    View in: PubMed
    Score: 0.608
  7. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013 Oct 01; 119(19):3479-88.
    View in: PubMed
    Score: 0.543
  8. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 08 17; 22(8):1073-1113.
    View in: PubMed
    Score: 0.222
  9. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol. 2020 10 10; 38(29):3398-3406.
    View in: PubMed
    Score: 0.220
  10. Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification. Neurol Clin. 2020 02; 38(1):95-113.
    View in: PubMed
    Score: 0.211
  11. A low percentage of metastases in deep brain and temporal lobe structures. Neuro Oncol. 2019 05 06; 21(5):640-647.
    View in: PubMed
    Score: 0.203
  12. Imaging and diagnostic advances for intracranial meningiomas. Neuro Oncol. 2019 01 14; 21(Suppl 1):i44-i61.
    View in: PubMed
    Score: 0.199
  13. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. AJR Am J Roentgenol. 2018 12; 211(6):1342-1347.
    View in: PubMed
    Score: 0.196
  14. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018 10 02; 91(14):e1355-e1359.
    View in: PubMed
    Score: 0.194
  15. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro Oncol. 2018 08 02; 20(9):1262-1271.
    View in: PubMed
    Score: 0.193
  16. Imaging in neuro-oncology. Ther Adv Neurol Disord. 2018; 11:1756286418759865.
    View in: PubMed
    Score: 0.187
  17. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 01; 19(1):109-117.
    View in: PubMed
    Score: 0.167
  18. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016 12; 18(12):1680-1687.
    View in: PubMed
    Score: 0.165
  19. How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol. 2015 Apr; 17(4):343.
    View in: PubMed
    Score: 0.153
  20. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014 Aug; 119(1):149-58.
    View in: PubMed
    Score: 0.144
  21. Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. Neuro Oncol. 2022 02 01; 24(2):289-299.
    View in: PubMed
    Score: 0.062
  22. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 01 05; 24(1):101-113.
    View in: PubMed
    Score: 0.061
  23. Corrigendum to: Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. Neuro Oncol. 2021 Dec 01; 23(12):2124.
    View in: PubMed
    Score: 0.061
  24. Analysis of morphological characteristics of IDH-mutant/wildtype brain tumors using whole-lesion phenotype analysis. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab088.
    View in: PubMed
    Score: 0.059
  25. Response to Letter to Editor. Neuro Oncol. 2020 11 26; 22(11):1706-1707.
    View in: PubMed
    Score: 0.057
  26. Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data. Neuro Oncol. 2020 10 14; 22(10):1536-1544.
    View in: PubMed
    Score: 0.056
  27. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro Oncol. 2020 09 29; 22(9):1262-1275.
    View in: PubMed
    Score: 0.056
  28. Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol. 2020 06 09; 22(6):757-772.
    View in: PubMed
    Score: 0.055
  29. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
    View in: PubMed
    Score: 0.054
  30. Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro Oncol. 2019 11 04; 21(11):1412-1422.
    View in: PubMed
    Score: 0.053
  31. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250.
    View in: PubMed
    Score: 0.048
  32. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro Oncol. 2018 08 02; 20(9):1162-1172.
    View in: PubMed
    Score: 0.048
  33. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017 Nov 29; 19(12):1688-1697.
    View in: PubMed
    Score: 0.046
  34. Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging. Clin Cancer Res. 2018 03 01; 24(5):1073-1081.
    View in: PubMed
    Score: 0.046
  35. Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017; 12(11):e0187908.
    View in: PubMed
    Score: 0.046
  36. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756.
    View in: PubMed
    Score: 0.045
  37. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagn Pathol. 2016 Jan 27; 11:13.
    View in: PubMed
    Score: 0.041
  38. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-e542.
    View in: PubMed
    Score: 0.040
  39. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
    View in: PubMed
    Score: 0.036
  40. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol. 2013 Nov; 115(2):267-76.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.